|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EED |
Gene summary for EED |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EED | Gene ID | 8726 |
| Gene name | embryonic ectoderm development | |
| Gene Alias | COGIS | |
| Cytomap | 11q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O75530 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8726 | EED | LZE2D | Human | Esophagus | HGIN | 1.13e-02 | 2.57e-01 | 0.0642 |
| 8726 | EED | LZE4T | Human | Esophagus | ESCC | 1.66e-11 | 1.27e-01 | 0.0811 |
| 8726 | EED | LZE7T | Human | Esophagus | ESCC | 8.79e-04 | 1.66e-01 | 0.0667 |
| 8726 | EED | LZE8T | Human | Esophagus | ESCC | 5.30e-05 | 6.76e-02 | 0.067 |
| 8726 | EED | LZE22T | Human | Esophagus | ESCC | 5.21e-04 | 2.15e-01 | 0.068 |
| 8726 | EED | LZE24T | Human | Esophagus | ESCC | 4.09e-21 | 3.67e-01 | 0.0596 |
| 8726 | EED | P2T-E | Human | Esophagus | ESCC | 4.69e-10 | 1.06e-01 | 0.1177 |
| 8726 | EED | P4T-E | Human | Esophagus | ESCC | 2.44e-14 | 3.21e-01 | 0.1323 |
| 8726 | EED | P5T-E | Human | Esophagus | ESCC | 1.21e-06 | 1.44e-01 | 0.1327 |
| 8726 | EED | P8T-E | Human | Esophagus | ESCC | 2.85e-05 | 9.42e-02 | 0.0889 |
| 8726 | EED | P9T-E | Human | Esophagus | ESCC | 2.54e-06 | 7.01e-02 | 0.1131 |
| 8726 | EED | P10T-E | Human | Esophagus | ESCC | 8.79e-14 | 1.95e-01 | 0.116 |
| 8726 | EED | P11T-E | Human | Esophagus | ESCC | 4.55e-09 | 2.43e-01 | 0.1426 |
| 8726 | EED | P12T-E | Human | Esophagus | ESCC | 7.41e-17 | 2.37e-01 | 0.1122 |
| 8726 | EED | P15T-E | Human | Esophagus | ESCC | 2.09e-13 | 1.15e-01 | 0.1149 |
| 8726 | EED | P16T-E | Human | Esophagus | ESCC | 1.05e-15 | 1.65e-01 | 0.1153 |
| 8726 | EED | P17T-E | Human | Esophagus | ESCC | 3.27e-05 | 2.64e-01 | 0.1278 |
| 8726 | EED | P19T-E | Human | Esophagus | ESCC | 6.72e-06 | 2.17e-01 | 0.1662 |
| 8726 | EED | P20T-E | Human | Esophagus | ESCC | 3.85e-07 | 2.30e-02 | 0.1124 |
| 8726 | EED | P21T-E | Human | Esophagus | ESCC | 1.51e-14 | 2.97e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00182057 | Esophagus | HGIN | peptidyl-lysine modification | 88/2587 | 376/18723 | 2.99e-07 | 1.39e-05 | 88 |
| GO:00165708 | Esophagus | HGIN | histone modification | 92/2587 | 463/18723 | 1.70e-04 | 3.30e-03 | 92 |
| GO:00349688 | Esophagus | HGIN | histone lysine methylation | 27/2587 | 115/18723 | 3.51e-03 | 3.24e-02 | 27 |
| GO:00064798 | Esophagus | HGIN | protein methylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
| GO:00082138 | Esophagus | HGIN | protein alkylation | 38/2587 | 181/18723 | 5.05e-03 | 4.22e-02 | 38 |
| GO:00180227 | Esophagus | HGIN | peptidyl-lysine methylation | 29/2587 | 131/18723 | 6.22e-03 | 4.95e-02 | 29 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:00165718 | Esophagus | ESCC | histone methylation | 89/8552 | 141/18723 | 2.17e-05 | 1.87e-04 | 89 |
| GO:003496814 | Esophagus | ESCC | histone lysine methylation | 72/8552 | 115/18723 | 1.85e-04 | 1.18e-03 | 72 |
| GO:001802214 | Esophagus | ESCC | peptidyl-lysine methylation | 79/8552 | 131/18723 | 5.17e-04 | 2.86e-03 | 79 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00064797 | Oral cavity | OSCC | protein methylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00082137 | Oral cavity | OSCC | protein alkylation | 92/7305 | 181/18723 | 7.86e-04 | 4.26e-03 | 92 |
| GO:00434142 | Oral cavity | OSCC | macromolecule methylation | 149/7305 | 316/18723 | 1.82e-03 | 8.60e-03 | 149 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EED | SNV | Missense_Mutation | novel | c.359N>C | p.Arg120Thr | p.R120T | O75530 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| EED | SNV | Missense_Mutation | novel | c.1139N>A | p.Arg380Gln | p.R380Q | O75530 | protein_coding | tolerated(0.26) | possibly_damaging(0.687) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EED | SNV | Missense_Mutation | c.752T>C | p.Ile251Thr | p.I251T | O75530 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| EED | SNV | Missense_Mutation | c.424N>A | p.Asp142Asn | p.D142N | O75530 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| EED | SNV | Missense_Mutation | c.230N>G | p.Lys77Arg | p.K77R | O75530 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-E2-A15E-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| EED | insertion | Nonsense_Mutation | novel | c.823_824insTGGGGTGACCAAAGAGCACTGCCTTGGAATAGGGGG | p.Lys275delinsMetGlyTerProLysSerThrAlaLeuGluTerGlyGlu | p.K275delinsMG*PKSTALE*GE | O75530 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| EED | SNV | Missense_Mutation | novel | c.196N>G | p.Lys66Glu | p.K66E | O75530 | protein_coding | deleterious(0.02) | benign(0.091) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EED | SNV | Missense_Mutation | novel | c.350N>A | p.Gly117Glu | p.G117E | O75530 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EED | deletion | Frame_Shift_Del | novel | c.880delA | p.Ile294SerfsTer22 | p.I294Sfs*22 | O75530 | protein_coding | TCGA-EK-A2GZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| EED | SNV | Missense_Mutation | novel | c.228N>T | p.Lys76Asn | p.K76N | O75530 | protein_coding | tolerated(0.11) | benign(0.011) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8726 | EED | ENZYME, CLINICALLY ACTIONABLE | MAK683 | |||
| 8726 | EED | ENZYME, CLINICALLY ACTIONABLE | ASTEMIZOLE | ASTEMIZOLE | 25369470 | |
| 8726 | EED | ENZYME, CLINICALLY ACTIONABLE | allosteric modulator | 387065597 | ||
| 8726 | EED | ENZYME, CLINICALLY ACTIONABLE | inhibitor | 336446911 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |